Streetbeat News

Products Services

RNXT

RenovoRx announced interim Phase III data showing that RenovoGem delays cancer progression by eight months in locally advanced pancreatic cancer. The results also showed a six-month overall survival benefit with RenovoGem versus systemic chemotherapy, and a 65% reduction in adverse effects. This highlights RenovoGem's potential to change the treatment paradigm for locally advanced pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 12:02 pm

COST

NFLX

Costco Wholesale Corporation (NASDAQ:COST) is implementing stricter measures to prevent card-sharing among customers, following a trend set by companies like Netflix Inc (NASDAQ:NFLX). Costco now requires photo identification and customers' membership cards at its self-checkout registers. The move aims to prevent nonmembers from reaping the benefits and pricing available to the members. In 2022, Costco generated $4.2 billion in sales from membership fees, up 9% Y/Y.

Portfolio Pulse from Vandana Singh

June 29, 2023 | 11:49 am

SSNLF

TSM

Taiwan Semiconductor Manufacturing Company Ltd (TSMC) is accelerating the construction of its $40 billion factory in Arizona, with operations expected to start by 2024. The company is sending more workers from Taiwan to the US to facilitate this. A second facility is expected to produce 3-nanometre chips by 2026. TSMC's investment aligns with US President Joe Biden's plans to boost domestic semiconductor production. Meanwhile, Samsung Electronics is expanding its chip foundry business, planning to introduce 2-nanometer production for mobile phone parts by 2025.

Portfolio Pulse from Anusuya Lahiri

June 29, 2023 | 11:40 am

BLNK

CHPT

EVGO

F

GM

RIVN

TSLA

VLVLY

Tesla has developed its proprietary North American Charging Standard (NACS) connector and aims to establish it as a continent-wide charging standard. Several automakers including Tesla, Aptera Motors, Ford, General Motors, Rivian, and Volvo have adopted or plan to adopt the NACS connector. EV charging networks such as Blink Charging, ChargePoint, and EVgo have also committed to offering NACS charging solutions. Automakers including Hyundai, Lucid, Mercedes-Benz, Stellantis, and Toyota are considering the adoption of the NACS connector.

Portfolio Pulse from Ramakrishnan M

June 29, 2023 | 11:33 am

CRVS

Corvus Pharmaceuticals has announced new preclinical data for Ciforadenant, highlighting its mechanism of action and synergy with immune checkpoint inhibitors. The announcement was made at the JCA-AACR Precision Cancer Medicine International Conference.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 11:15 am

ALDX

Aldeyra Therapeutics has announced positive topline results from the Phase 2 trial of intravitreal ADX-2191 for Retinitis Pigmentosa, showing statistically significant improvement in retinal function relative to baseline.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 11:12 am

DNA

Ambrosia Bio has partnered with Ginkgo Bioworks to develop an expression strain for the scalable production of Ambrosia Bio's proprietary enzymes. These enzymes are used for the conversion of feedstock into allulose.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 11:10 am

CANF

Can-Fite has received positive feedback from the FDA regarding the development and registration plans for Piclidenoson. The FDA has encouraged the company to enroll adolescent patients due to the strong safety profile of the drug demonstrated over its development history and prior studies.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 11:05 am

PSTV

Plus Therapeutics, Inc. (PSTV) reported positive interim updates from two clinical studies evaluating its lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma and leptomeningeal metastases. The updates were presented at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 11:04 am

GNTA

Genenta Science has received Orphan Drug Designation from the European Commission for Temferon, a treatment for glioma. This designation could provide Genenta with various benefits, including market exclusivity for a period after product approval.

Portfolio Pulse from Benzinga Newsdesk

June 29, 2023 | 11:03 am